As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.
13 Analysts have issued a AVITA Therapeutics forecast:
13 Analysts have issued a AVITA Therapeutics forecast:
Mar '25 |
+/-
%
|
||
Revenue | 72 72 |
41%
41%
|
|
Gross Profit | 62 62 |
43%
43%
|
|
EBITDA | -49 -49 |
0%
0%
|
EBIT (Operating Income) EBIT | -51 -51 |
2%
2%
|
Net Profit | -57 -57 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
Head office | United States |
CEO | James Corbett |
Employees | 260 |
Founded | 1992 |
Website | www.avitamedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.